Summary & Overview
CPT 95913: Nerve Conduction Studies, 13 or More
CPT code 95913 represents nerve conduction studies involving 13 or more individual tests, a procedure commonly performed in neurology to diagnose and evaluate a wide range of peripheral nerve disorders. This code is significant nationally due to its role in identifying conditions such as carpal tunnel syndrome, polyneuropathy, and neuralgia, which affect millions of Americans. The procedure is typically conducted in an office setting and is integral to the clinical workup for patients presenting with symptoms of nerve dysfunction.
Major payers covering this service include Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare. The publication provides a comprehensive overview of payer coverage, billing practices, and clinical context for 95913. Readers will gain insights into current benchmarks, policy updates, and the clinical importance of nerve conduction studies. The article also highlights common modifiers used in billing, associated physician taxonomies, relevant ICD-10 diagnoses, and related CPT codes, offering a complete picture of how this procedure fits into the broader landscape of neurology services and medical billing.
This summary equips healthcare professionals, billing specialists, and policy analysts with the essential information needed to understand the utilization and reimbursement landscape for nerve conduction studies, ensuring clarity on payer requirements and clinical indications.
CPT Code Overview
CPT code 95913 is used to report nerve conduction studies involving 13 or more studies. This procedure is a key diagnostic tool in neurology, allowing clinicians to assess the function and integrity of peripheral nerves. The typical site of service for this code is the office setting (POS 11), where specialized equipment and expertise are available to perform comprehensive nerve conduction testing. These studies are essential for evaluating patients with suspected neuropathies, nerve injuries, or other neurological disorders.
Clinical & Coding Specifications
Clinical Context
A patient presents to a neurology office with symptoms such as numbness, tingling, or weakness in the extremities. The neurologist suspects a peripheral nerve disorder, such as carpal tunnel syndrome, polyneuropathy, or neuralgia. To evaluate the function of multiple nerves, the provider performs nerve conduction studies, completing 13 or more individual studies as part of a comprehensive assessment. This procedure is typically performed in an office setting (Place of Service 11) by a physician specializing in neurology, clinical neurophysiology, or neurodevelopmental disabilities.
Coding Specifications
-
Modifiers:
26: Professional Component – Used when only the physician's interpretation and report are billed.TC: Technical Component – Used when only the technical portion (equipment, technician) is billed.59: Distinct Procedural Service – Used to indicate a procedure or service was distinct or independent from other services performed on the same day.76: Repeat Procedure by Same Physician – Used when the same physician repeats the procedure.
-
Provider Taxonomies:
Taxonomy Code Specialty Name 2084N0400XNeurology Physician 2081N0008XClinical Neurophysiology Physician 2084P2900XNeurodevelopmental Disabilities Physician
Related Diagnoses
-
G56.00: Carpal tunnel syndrome, unspecified upper limb- Relevant for patients with symptoms of median nerve compression, often evaluated with nerve conduction studies.
-
G57.00: Lesion of sciatic nerve, unspecified lower limb- Indicates possible sciatic nerve dysfunction; nerve conduction studies help localize and assess severity.
-
G60.9: Hereditary and idiopathic neuropathy, unspecified- Used for patients with unexplained neuropathy; nerve conduction studies assist in diagnosis.
-
G62.9: Polyneuropathy, unspecified- Applies to patients with widespread nerve dysfunction; nerve conduction studies quantify extent and pattern.
-
M79.2: Neuralgia and neuritis, unspecified- For patients with nerve pain or inflammation; nerve conduction studies help differentiate causes.
Related CPT Codes
95886: Needle electromyography, each extremity – Often performed alongside nerve conduction studies to assess muscle and nerve function.95860: Needle electromyography, one extremity – Used for focused assessment; may be combined with nerve conduction studies.95911: Nerve conduction studies; 9-10 studies – Used when fewer studies are performed; alternative to95913for less extensive testing.95912: Nerve conduction studies; 11-12 studies – Used when 11-12 studies are performed; alternative to95913for slightly less comprehensive testing.95907: Nerve conduction studies; 1-2 studies – Used for minimal testing; not typically performed with95913but may be used in separate clinical scenarios.
Codes 95886 and 95860 are commonly used together with 95913 for a complete electrodiagnostic evaluation. Codes 95911, 95912, and 95907 are alternatives based on the number of studies performed.
National Reimbursement Benchmarks
Nationally, the mean rate for CPT code 95913 is highest among UnitedHealth Group at $326.20, followed by Cigna at $317.63. The average commercial benchmark (BUCA) stands at $277.23, which is notably higher than the Medicare mean rate of $207.23. This highlights a substantial gap between commercial and government reimbursement levels for this service.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies across payers. Medicare shows the widest spread at $167.50, indicating significant variability in rates. Among commercial payers, Cigna and UnitedHealth Group also exhibit wide dispersions ($169.33 and $163.67, respectively), while Aetna has the tightest range at $91.93. This suggests that Aetna's rates are more consistent nationally compared to other payers.
The table and chart below present a detailed breakdown of national benchmarks for CPT code 95913 across major payers.
State Benchmarks
State: AK1 / 50
Alaska Benchmarks
Alaska exhibits a notably wide rate spread for CPT code 95913, especially among commercial payers. For example, Blue Cross Blue Shield's 75th percentile rate is $576.50, while its 25th percentile is $379.59, resulting in a spread of $196.91. UnitedHealth Group also shows a substantial spread, with a 75th percentile of $524.67 and a 25th percentile of $487.33. This indicates significant variability in negotiated rates across providers in the state.
Compared to national averages, Alaska's commercial payers consistently reimburse at much higher rates. UnitedHealth Group, Blue Cross Blue Shield, and Aetna all have mean rates well above their national benchmarks. The table and chart below present the full breakdown of payer-specific rates for Alaska, highlighting these differences and the range of reimbursement values across the state.
Key Insights for Alaska
- UnitedHealth Group offers the highest mean reimbursement rate for CPT 95913 in Alaska at $535.88, while Medicare is the lowest at $201.19.
- All commercial payers in Alaska reimburse significantly above their respective national averages, with UnitedHealth Group and Blue Cross Blue Shield showing the largest positive deviations.
- The rate spread is widest for Blue Cross Blue Shield, indicating substantial variability in negotiated rates across providers.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.